Activation-induced cytidine deaminase (AID) is essential and sufficient to accomplish class-switch recombination and somatic hypermutation, which are two genetic events required for the generation of antibody-mediated memory responses. However, AID can also introduce genomic instability, giving rise to chromosomal translocation and/or mutations in proto-oncogenes. It is therefore important for cells to suppress AID expression unless B lymphocytes are stimulated by pathogens. The mechanisms for avoiding the accidental activation of AID and thereby avoiding genomic instability can be classified into three types: (i) transcriptional regulation, (ii) post-transcriptional regulation and (iii) target specificity. This review summarizes the recently elucidated comprehensive transcriptional regulation mechanisms of the AID gene and the post-transcriptional regulation that may be critical for preventing excess AID activity. Finally, we discuss why AID targets not only Igs but also other proto-oncogenes. AID targets many genes but it is not totally promiscuous and the criteria that specify its targets are unclear. A recent finding that a non-B DNA structure forms upon a decrease in topoisomerase 1 expression may explain this paradoxical target specificity determination. Evolution has chosen AID as a mutator of Ig genes because of its efficient DNA cleavage activity, even though its presence increases the risk of genomic instability. This is probably because immediate protection against pathogens is more critical for species survival than complete protection from the slower acting consequences of genomic instability, such as tumor formation.
Introduction
Activation-induced cytidine deaminase (AID), encoded by the Aicda gene, is a key molecule for generating 'antibody memory', which is critical for effective vaccination (1, 2) . AID is essential for inducing both class-switch recombination (CSR), which relies on switch (S) regions, and somatic hypermutation (SHM), which occurs in variable (V) regions; AID deficiency in mice and humans causes substantial immune deficiency with the complete absence of CSR and SHM (3, 4) . Patients with an AID deficiency manifest hyperIgM syndrome type II and suffer from recurrent infections. When AID is expressed in non-B cells that carry the appropriate assay constructs for SHM or CSR, the cells can undergo SHM or CSR, respectively (5, 6) . Therefore, AID is the single unique molecule required for CSR and SHM. In other words, the genetic alterations that bring about antibody memory are carried out by a collaboration between the B-cell-specific factor AID and other ubiquitously expressed factors, such as DNA repair enzymes (7) .
AID has two separate functions in CSR: the DNA cleavage of target loci and the correct pairing of cleaved ends. The DNA cleavage activity is localized to the N-terminal portion of AID because the C-terminal truncation of AID retains the DNA cleavage (and SHM) activities but blocks complete CSR (8) (9) (10) . C-terminally truncated or mutated AID cannot accomplish the appropriate re-ligation of the cleaved S regions and instead mediates an augmented aberrant recombination, such as the Myc-Igh translocation (10) . These findings indicate that the C-terminal portion of AID is responsible for appropriately pairing the cleaved DNA ends that are repaired and re-ligated through the collaboration of many enzymes.
Since AID has a single catalytic center, it is most likely that the two activities are catalyzed by the same catalytic center with different cofactors. On the other hand, a mutant of AID called G23S has relatively weak DNA cleavage activity and thus severely reduces SHM, but the CSR activity is relatively intact (11) . This phenotype of G23S may be attributable to the cleavage efficiency of the S region being much higher than that of the V region (10) . Interestingly, SHM is augmented in the absence of the C-terminal portion of AID (8, 10, 12) , probably because the C-terminally truncated molecule loses its end-pairing function, which results in the catalytic center having DNA cleavage as its sole activity.
The molecular mechanism of DNA cleavage by AID has been extensively debated (4, (13) (14) (15) (16) (17) . The DNA deamination model proposes that AID binds to target DNA and deaminates dC to dU, thus creating a U-G mismatch. This triggers the base excision repair pathway, consisting of uracil DNA glycosylase and apurinic-apyrimidinic endonuclease, followed by the activation of error-prone DNA repair pathways. On the other hand, the RNA-editing hypothesis proposes that AID edits RNA, and the resultant product is involved in DNA cleavage at the target loci.
In any case, it is clear that the DNA-cleaving activity of AID does not have any specific recognition sequence because neither the V nor the S region contains any consensus cleavage sites (1) . In addition, no clear binding specificity of AID to DNA has been demonstrated. Thus, AID is a potential mutator and therefore dangerous. In fact, AID over-expression can cause mutations and chromosomal translocations, resulting in genomic instability and tumors (18) (19) (20) (21) (22) . By contrast, AID deficiency reduces the frequency of tumorigenesis (23) (24) (25) (26) .
In this review, we focus on the genomic instability induced by AID and discuss what mechanisms may prevent AID from performing this aberrant function. The mechanisms regulating AID function fall into three categories: transcriptional regulation, post-transcriptional regulation and target selection mechanisms.
AID induces genomic instability not only in B cells but also in cells of other lineages
The targets of AID mutagenesis are not limited to Ig genes, given that several proto-oncogenes are frequently mutated or translocated to Ig loci in B-cell tumors that express AID (27) . The requirement for AID to achieve chromosomal translocations such as Myc-Igh, a critical step for tumor development, was demonstrated using AID-deficient mice (23, 25, (28) (29) (30) .
In addition, the over-expression of AID in various organs by transgenic systems leads to tumor development with frequent chromosomal translocations and/or gene mutations (18) (19) (20) (21) (22) . The incidence of B-cell tumor development in animal models is much reduced under AID-deficient conditions (24, 26) . Interestingly, the BCR-ABL1 kinase encoded by the Philadelphia chromosome, a hallmark of acute lymphatic leukemia (ALL), can induce Aicda expression, and cases of ALL in which AID is expressed have a worse prognosis than those without it (31, 32) . A number of reports on AID expression in various B-cell lymphomas and leukemias show an association between AID expression and a poor prognosis (27, 33, 34) . Collectively, these results suggest that AID is involved in tumorigenesis and affects the prognosis of patients with B-cell lymphomas or leukemias.
Although AID expression is normally restricted to activated B cells, the 'accidental firing' of AID and consequent DNA damage in many cell types have been reported, suggesting that AID may influence tumors originating from a wider variety of cells. Infection by viruses or bacteria as well as stimulation by pro-inflammatory cytokines can induce Aicda expression. Epstein-Barr virus infection induces AID expression via a viral protein, latent membrane protein 1, which mimics cellular CD40 and evokes ligand-independent signaling in B cells, thereby inducing AID expression (35, 36) . The infection of bone-marrow cells by Abelson murine leukemia virus (Ab-LMV) also induces the expression of AID in B cells (37) , which does not appear to be due to the v-abl kinase, a viral oncogene, because AID is also induced by infection with Moloney murine leukemia virus (Mo-MLV), which does not carry v-abl (38) . Moreover, a non-retrovirus, hepatitis C virus, also induces AID expression in infected B cells (39) .
Furthermore, some epithelial cell lines are prone to AID induction. Endo et al. (40) found that tumur necrosis factor (TNF)-a treatment and/or transfection of the hepatitis C virus genome induces AID in a human hepatocyte line. Strikingly, infection with Helicobacter pylori, which is known to trigger gastric cancer development, induces AID expression and causes an accumulation of mutations in the TP53 tumor suppressor gene in gastric epithelial cells (41, 42) . This AID induction requires infection by highly virulent 'cag' (pathogenicity island)-positive H. pylori, implying an association between bacterial pathogenesis and AID expression.
It is unknown whether the AID expression that occurs upon pathogen infection and inflammation gives any advantage to non-B cells, which do not express Ig. AID may protect cells from transformation by Ab-LMV (37) . Although the precise mechanism for this phenomenon remains elusive, it might be similar to the process by which the APOBEC3 family of cytidine deaminases acts against retroviruses like HIV ( [43] [44] [45] .
The regulation of AID expression is less tight than originally thought, given that immature B cells, which have not yet been exposed to antigens, express AID, although the expression level is less than one hundredth of that in germinal center B cells (46) (47) (48) . In spite of its low levels, the AID expressed in immature B cells is thought to contribute to the diversification of the Ig repertoire by mutating IgV regions, perhaps in an antigen non-specific manner (46, 49, 50) . A low level of AID mRNA is also detectable in oocytes (51) . Although its function in oocytes has not been clearly demonstrated, it may play a role in epigenetic regulation through the demethylation of DNA (51) (52) (53) . However, so far, no developmental abnormality of mouse AID-null embryos has been reported.
Transcriptional regulation of AID

Conserved regions in and around the Aicda gene
By comparing the nucleotide sequences surrounding the Aicda loci of various species, four well-conserved regions that contain more than a dozen transcription factor-binding motifs have been identified (Fig. 1 ). These regions are designated as follows: region 1 (i.e. the Aicda promoter and the region immediately upstream), region 2 (i.e. regulatory elements in the first intron), region 3 (i.e. the area between ;6-and 25-kb downstream from exon 5 in mice and humans, respectively) and region 4 [i.e. the area ;8-kb upstream of the transcription start site (TSS)] (54, 55).
Crouch et al. (48) analyzed the H3 acetylation pattern by wide range scanning using a chromatin immunoprecipitation (ChIP) assay. The hyper-acetylated H3 areas that appeared upon LPS stimulation overlapped with regions 1-3. Tran et al. (55) performed a luciferase reporter assay of these regions and found functional transcription factor-binding motifs in regions 1, 2 and 4, which were further investigated. The precise role of region 3 was not clear from the luciferase assays, although its deletion reduces AID expression from transgenic BAC constructs (55) .
Region 1, which contains a TATA-less promoter and the TSS, does not account for the specific expression of AID because it can promote AID transcription in both B cells and non-B cells, in luciferase assays (54, 55) . In fact, binding sites for the ubiquitously expressed transcription factors Sp1 and Sp3 are mapped to region 1.
A well-conserved HoxC4-Oct motif is located in region 1 downstream of the Sp sites and upstream of the TSS. HoxC4 is preferentially expressed in germinal center B cells, in contrast to Sp1 and Sp3, and CSR is impaired in association with low AID levels in HoxC4-knockout mice (56) . In a luciferase reporter assay using plasmids that containing the Aicda promoter and the SV40 enhancer, the HoxC4-Oct motif was shown to be required for higher expression levels of AID. However, the same construct without the virus enhancer does not seem to support strong expression from the reporter plasmid (56) . Moreover, the luciferase activity regulated by region 1, which includes the HoxC4-Oct site, is not enhanced by CD40L, IL-4 and transforming growth factor (TGF)-b in CH12F3-2 cells, although these stimuli are strong inducers of AID in this cell line as well as in normal B cells (55) . In addition, the HoxC4 mRNA levels of germinal center and naive B cells are similar (55) . Taken together, these results indicate that HoxC4-Oct is probably required for the efficient expression of AID, but it may not play the major role in AID's induction by stimuli that lead to CSR.
B-cell-specific positive regulatory elements
Region 2, which is located in the first intron, contains binding motifs for E-proteins (E-box) and Pax5, which are both essential for B-cell development (57, 58) (Fig. 1) . The overexpression of the E47 protein, an isoform of E2A, in in vitroactivated B cells augments Aicda expression. Inversely, the inhibition of E-protein function by introducing Id2 or Id3 substantially represses Aicda expression (57, 58) . The binding of E47 to these sites was confirmed by an electrophoretic mobility shift assay (EMSA) and ChIP with activated mouse spleen B cells (57) .
Curiously, B cells from aged mice showed a reduction in E47 and Aicda expression, resulting in inefficient CSR (59). Hauser et al. (60) showed that cross-linking of surface Ig induced calcium signaling through calmodulin, which inhibited E2A protein function and consequently AID expression. This observation may reflect a biological regulation mechanism for turning off AID when high-affinity antibodies are generated by SHM. Unexpectedly, knockout of the E2A protein from mouse B cells or DT40 cells (a chicken B lymphoma cell line) does not cause a reduction in AID expression (61, 62) , suggesting that other E-proteins, E2-2 and HEB, may replace E2A in the regulation of Aicda transcription (62) .
The forced over-expression of Pax5 in BaF/3 cells induces AID transcription (58) (58, 63) . However, another group reevaluated Pax5 binding to region 1 in a well-controlled EMSA experiment and concluded that this site is in fact the Sp protein-binding site (54) . The transcription enhancer activity of the Pax5-binding site and E boxes in region 2 was conclusively demonstrated by a luciferase reporter assay (55) . Importantly, the transcription reporter constructs carrying the E2A and Pax5 elements elicit a substantially higher signal in a B-cell line than in non-B-cell lines (55) . These data are consistent with the notion that the Pax5-binding sites and E protein-binding sites in region 2 are critical for conferring B lineage-cell specificity on Aicda expression (Fig. 1) .
Transcription elements responsible for environmental stimulation
The transcription enhancer activity of region 4 was clearly demonstrated by the observation of strong luciferase expression when CH12F3-2 cells were stimulated by CD40L, IL-4 and/or TGF-b. No other regions showed the induced expression of luciferase activity, indicating that the enhancers in this region have a primary role in the induction of AID by environmental stimuli. The major transcription factors that mediate the signals initiated by CD40L, IL-4 and TGF-b stimuli are nuclear factor-jB (NF-jB), STAT6 and the Smad proteins, respectively (64) (65) (66) . Since putative binding motifs for these factors are easily identified in region 4, the function of each motif was evaluated and confirmed by detailed luciferase reporter assays and by ChIP assays (55) .
In addition to the predicted elements discussed above, the importance of tandem C/EBP-binding sites located between the NF-jB sites and Smad3/4 sites was also revealed by luciferase assay. Disruption of one of the two C/EBP sites causes the complete loss of enhancer activity under both stimulated and non-stimulated conditions, although the tandem C/EBP sites alone do not show any enhancer activity for the Aicda promoter (55) . Taking these observations together, the pair of C/EBP sites seems to be required for the activating function of the transcription factors, NF-jB, STAT6 and Smads (Fig. 1) . The C/EBPs are reported to work synergistically with other transcription factors. For example, NF-jB and STAT6 function synergistically with C/EBPb at the Cox2 gene and the Ie promoter of IgH for germ line transcription (67, 68) . However, the precise molecular mechanism by which the C/EBPs collaborate with other factors to initiate transcription of the Aicda gene remains to be clarified.
A potential NF-jB-binding site is found ;1.4-kb upstream of the TSS in region 1 (38, 55, 69) . This NF-jB site was suggested to be responsible for the cell's response to viral infection and TNF-a signaling (38, 70) . Gourzi et al. (38) showed that AID is induced upon infection by Ab-MLV or Mo-MLV and that this induction does not depend on IFNs.
Furthermore, the stimulation of Toll-like receptors (TLRs) induces AID expression in B cells (38, 71) . Because the TLRs interact with virus components, virus components may induce AID expression through them. Surprisingly, the AID expression induced by Ab-MLV does not depend on Myd88 or Trif, which are critical signaling molecules for the TLRs, suggesting that a TLR-independent pathway is involved. NF-jB signaling is clearly required because NF-jB p50-knockout cells cannot induce AID upon Ab-MLV infection. Furthermore, the binding of the p50 subunit of NF-jB to the region 1 site in Ab-MLV-infected B cells was demonstrated by ChIP assay (38) . NF-jB p65 binding to this region was also suggested in a TNF-a-treated human B-cell line (70) .
However, the NF-jB element in region 1 seems to play only a minor role in CD40-induced AID expression because CD40 stimulation is dependent on the NF-jB site in region 4, which is far upstream of the Aicda promoter (55). The difference between the NF-jB signaling induced by virus infection versus CD40 stimulation is not clear. Whether the region 4 site is also used in the response to viral infections should be re-examined because the previous experiments were carried out before the NF-jB site in region 4 was known to exist.
The AID-inducing signals do not seem to be limited to inflammatory or CSR-inducing stimuli. Pauklin et al. reported that estrogen treatment induces a low level of AID expression in B cells as well as breast and ovary cells. The estrogen response element is found in the area adjacent to the NF-jB-binding site in region 1 (70) . The actual binding of the estrogen receptor to region 1 was suggested by EMSA and ChIP assays in estrogen-treated Ramos cells. However, since Ramos cells constitutively express AID regardless of the presence of estrogen, the role of the estrogen receptor in AID induction is not clear.
Ubiquitous silencers of Aicda
The mechanism for suppressing AID expression in non-B cells requires silencing activity. When a luciferase assay was performed with a reporter plasmid carrying the Aicda promoter and region 2, transcription activity was substantially repressed despite the presence of the Pax5 and E-box elements (55, 58) . Tran et al. (55) mapped the silencing activity to the c-Myb-and E2f-binding motifs located adjacent to the Pax5 motif and the E boxes, by introducing deletions and mutations into region 2. The transcription factor c-Myb can function as a transcription repressor for many genes, including Cd4, Nras and c-erbB-2 (72-74). In addition, some members of the E2f protein family can function as transient or stable repressors (75, 76) . These repressor proteins are expressed rather ubiquitously. Interestingly, the mRNAs for E2f7 and E2f8 increase in splenic B cells upon CSR stimulation (55) . Taken together, the silencing-dominant nature of region 2 could explain why resting B cells do not express AID, despite their expression of the Pax5 and E-proteins.
The intronic silencer elements also counteract environmental stimulus-responsive enhancer activity, indicating that the silencers constitutively function against both stimulationdependent and B-cell-intrinsic activities (55) . The role of these silencers is to safeguard the genome from instability. Unfortunately, however, the repression by the silencers is not complete, and accidental firing is inevitable, even in the presence of the silencers.
Indirect regulation of B-cell-specific Aicda expression
Some transcription factors or signals are known to have a role in Aicda regulation, but whether they regulate Aicda transcription directly or indirectly remains to be clarified. IFN regulatory factor (IRF)-4-knockout mice show a severe loss of CSR and impaired Aicda expression (77) . IRF-4 may act through E2A proteins because the high-affinity binding of IRF-4 to DNA has been observed only when it interacts with its partners, for example the Ets or E2A proteins (78, 79 
Post-transcriptional regulation
In addition to the sophisticated transcriptional regulation of Aicda expression, AID is further regulated posttranscriptionally. Although the mechanism of this regulation is still unclear, its importance was suggested by experiments using transgenic mice in which AID was constitutively expressed only in B cells (83, 84) . AID mRNA and protein levels comparable to those in wild-type activated B cells were observed in the resting B cells of these transgenic mice, yet no significant SHM was detected in these cells, suggesting that the transgenic AID protein in resting B cells is less active.
These transgenic mice were crossed with AID-knockout mice to evaluate the protein activity derived from the transgene. SHM and CSR took place when the B cells were activated in vivo or in vitro, indicating that the transgene product was functional. However, the frequencies of SHM and CSR in these cells were severely reduced, suggesting the presence of a mechanism that down-modulates AID activity in B cells (83, 84) . Recently, it was reported that the over-expression of AID under the control of Ig-kappa chain regulatory elements in mouse B cells causes substantial SHM accumulation in the Igh gene even in resting B cells (18) . The Ig-kappa regulatory elements might therefore drive AID expression more strongly, overcoming the downmodulating activities of B cells.
Micro-RNA-155 and -181b were demonstrated to downmodulate AID expression post-transcriptionally (85) (86) (87) . A putative binding site for each of these micro-RNAs is located in the 3# untranslated region of the AID transcript. The targeted mutation of the putative micro-RNA-155-binding site causes stabilization of the mRNA and increases AID expression significantly in activated B cells (85, 86) , thereby enhancing CSR and SHM frequency; however, its influence in other immune cells is less dramatic. The major impact of this mutation, however, is that the Myc-Igh translocation frequency in activated B cells increases ;3-to 6-fold, suggesting that the binding of micro-RNA-155 is physiologically functional as a safeguard against genomic instability (85) .
AID activity might also be modulated by phosphorylation (88, 89) . Among several phosphorylation sites on AID, functional relevance has been suggested for serine 38 (S38) and threonine 140 (T140). Knock-in mice carrying an alanine (A) substitution at S38 or T140 have been generated. The S38A mutant mice exhibit ;20 to 30% of the wild-type activity for both CSR and SHM (90, 91) . The effect of the T140A mutation is less prominent, but it causes substantial reductions in CSR and SHM, as well. S38 and T140 are phosphorylated, respectively, by protein kinase A and C in vitro, which are not lymphoid-specific kinases. Consistent with this, both residues are constitutively phosphorylated on AID when it is expressed in non-lymphoid cells, such as fibroblasts and kidney cells (84, 90, 92) . It is still unclear, however, whether these modifications contribute to the physiological regulation of AID.
Aoufouchi et al. observed that the nuclear AID protein is polyubiquitinated, indicating that AID in the nucleus is rapidly degraded by the proteasome pathway (93) . The ubiquitination site, however, is not a lysine residue because an AID mutant in which all the lysine residues are replaced by arginine is still ubiquitinated. The actual ubiquitination sites should be clarified because it is possible that AID interacts with a polyubiquitinated protein, rather than being polyubiquitinated itself.
Mechanisms determining the target specificity of AID
The target specificity of AID is vague but not totally promiscuous. Several groups have shown that the over-expression of AID or continuous stimulation of B cells induces mutations in many genes, including Myc, Pim1, p53 and bcl6 in addition to the Ig genes (94) (95) (96) (97) . The maximum number of AID targets reported by Schatz's group was ;100, but it is clearly limited (98) . An important question is how the number of targets is restricted. There must be some recognition mechanism to limit the number of targets within the whole genome, and several possible mechanisms by which this limitation might be achieved have been proposed.
AID regulation to avoid the genomic instability 231
First, it is critical that the target be transcribed because both CSR and SHM are transcription dependent (1) . Second, although a mechanism whereby the DNA base sequence may contribute to target specificity remains a formal possibility, it is unlikely because it is almost impossible to identify any common sequences between the Ig V and S regions. There are several reports claiming that SHM hotspots have consensus sequences such as WRCH (99) (100) (101) (102) (103) (104) . However, it is impossible for such a short sequence to limit the number of target loci to a few hundred among the whole genome.
According to the DNA deamination model, AID binds to DNA directly; in vitro, AID can deaminate any DNA sequence. Some reports claim that the in vitro target specificity is similar to that identified in SHM (105) (106) (107) (108) (109) . AID can also mutate DNA in Escherichia coli (8, 13, 110, 111) . The target gene specificity of AID in E. coli is not clear, however (8, 13, 110, 111) . In vitro systems for measuring DNA deamination demonstrated that single-stranded rather than doublestranded DNA is preferred by AID (110, (112) (113) (114) . In addition, naked DNA is more efficiently targeted than chromatin-associated DNA (115) . This point is curious because most DNA is in the chromatin form in vivo, even when the target is transcribed.
Another proposed possibility is that the DNA structure per se determines the AID targets. The R-loop, which can be formed during transcription, was considered to be essential for AID targets (116, 117) . However, R-loop formation is not unique to Igs, although a GC-rich sequence, like that in S regions, is prone to form an R-loop. Nevertheless, it is still not clear whether the R-loop alone can provide enough specificity to explain AID target specificity.
More recently, an unusual form of DNA that is generally called a 'non-B' form, such as cruciform DNA, was proposed to be a target of AID cleavage (118) . This hypothesis is based on the observation that topoisomerase 1 (Top1) expression is decreased by AID activation. Top1 knockdown also enhances CSR and S region cleavage; however, more complete inhibition by the specific inhibitor of Top1, camptothecin, inhibits CSR. Because camptothecin is effective at an extremely low concentration (30 nM) and brief exposure (3 h), the inhibition is likely due to the specific effect to Top1. Top1 normally relaxes the tight negative supercoil downstream of the transcription machinery in the S region (118) . When Top1 expression is decreased, the tight negative supercoil in the downstream S region is not relaxed, which induces the formation of non-B DNA in the S region. In fact, bisulfite sensitivity (indicating a DNA structural change) is increased in the S region when B lymphoma (CH12F3-2) cells are stimulated by CD40 ligand, TGF-b and IL-4. A similar enhancement of bisulfite sensitivity in the S region is caused by Top1 knockdown. Top1 acts by cleaving, rotating and re-ligating one strand of DNA. The non-B form of DNA can still be cleaved by Top1, but the DNA's unusual structure blocks Top1's rotation around the helix, resulting in irreversible cleavage (Fig. 2) . This finding is consistent with the observation that constitutive Top1 knockdown causes genomic instability (119) .
How does AID down-modulate Top1? Since AID expression reduces the translation of Top1 mRNA by half, it was speculated that AID edits micro-RNA and that the edited micro-RNA may interact with the Top1 mRNA, resulting in its reduced translation. This proposed model explains many previous observations regarding the target specificity of AID: (i) the transcription dependency, (ii) the presence of DNA sequences that take on a non-B form, such as stemloop structures, at all the preferred targets of AID (Ig V and S loci and the Myc loci) (120, 121) and (iii) ability of a palindromic DNA sequence, e.g. a multiple cloning site sequence of a plasmid vector, to substitute the S region sequence (121) .
Why did evolution select AID as the enzyme that generates Ig diversity?
It is puzzling that such a dangerous molecule as AID was chosen to generate antibody diversity and to protect organisms from pathogens. The genomic instability induced by AID is a great threat to organisms because it can cause cell death and increases the risk of tumor formation. However, it usually takes a long time for tumors to form, and defense against pathogens must be a quick response. Infectious diseases are a more serious threat to an organism, especially because young individuals must be protected until they reproduce. Tumorigenesis normally takes place in the later stage of life, after reproduction has been completed. Therefore, evolution has selected a very efficient way to generate Ig diversity, even though it carries the risk of genomic instability. As long as the organism can survive until its reproductive age, tumorigenesis is not a threat to the survival of the species.
Conclusions
AID induces genomic instability although it plays an indispensable role in antibody diversification. AID expression is mostly restricted to activated B cells; however, a large body of evidence indicates that AID can be expressed even in non-B cells in certain conditions, such as in response to infection, inflammatory cytokines and hormones. To avoid harm to the organism by genomic damage, multiple safeguard systems appear to have evolved. 
